Viralytics Limited (ASX: VLA)


Viralytics (ASX: VLA) is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of specific viruses to preferentially infect and kill cancer cells. www.viralytics.com

Merck NYSE MRK Viralytics ASX VLA oncolytic immunotherapy biotech CAVATAK

Merck pays premium for breakthrough oncolytic immunotherapy developer Viralytics

One of the world’s largest biopharmaceutical companies has surprised the market by announcing a sweeping takeover of oncolytic immunotherapy dev...